Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research[1][2].
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Anifrolumab (67.7 nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation[2].
Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells[2].
Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively[2].
Anifrolumab (67.7 nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production[2].
| Western Blot Analysis[2]: | |
|
Cell Line: |
Peripheral blood mononuclear cells (PBMCs) |
|
Concentration: |
67.7 nM. |
|
Incubation Time: |
20 min. |
|
Result: |
Abrogated IFN-α2-dependent and pDC supernatant-dependent STAT1 phosphorylation. |
| Cell Differentiation Assay[2]: | |
|
Cell Line: |
Plasmacytoid dendritic cell (pDC) |
|
Concentration: |
1 and 10 μg/mL |
|
Incubation Time: |
6 or 7 days |
|
Result: |
Inhibited pDC-mediated plasma cell differentiation in a dose-dependent manner, with a mean 76% reduction in plasma cell number relative to control antibody. |
References:
[1]. Furie R, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386.
[2]. Riggs JM, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018 Apr 5;5(1):e000261.